Presented by
Elisa Kieback
Nominated by
Max Delbrück Center
T-knife has developed a special mouse strain that generates efficient anti-cancer molecules. Using these molecules the immune system of a cancer patient can be reprogrammed to attack tumor cells and eliminate them just like they would attack a virus-infected cell. T-knife’s technology has the potential to revolutionise the treatment of solid tumors just as CAR-T have for leukemia. T cell therapy has been shown to lead to complete remission of tumors in patients refractory to virtually any other available therapy. This gives hope to be able to treat patients which have no options left.